You will receive an email with the product attachment today, immediately after the payment is completed.
In stock
Product Details
Overview of and key conclusions from the extensive near-term newsflow expected for AstraZeneca, such as FY 2020 results on February 11 and the March 20 FDA action date for Evrenzo (roxadustat). Includes expected Alexion newsflow, which is of interest in light of AstraZeneca’s bid. The report captures Q1 as well as H1 2021e newsflow, with detail on likely outcome, expected timing and impact of each event. It features >40 expected events for AstraZeneca and 9 key items for Alexion. The report has been fact-checked by both AstraZeneca and Alexion.
The slide deck is accompanied by a 10-minute audio cast walking you through the slides.
Please contact us should you require bespoke services such as alternative cuts of the data or competitor newsflow.
